Showing results (11-20 of 33) with videos related to
Sort By:
Pageof 4
BJU International|September 24, 2013
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomesBradley J Atkinson, Diana H Cauley, Chaan Ng, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancerArlene O Siefker-Radtke, Randall E Millikan, Shi-Ming Tu, et al.Cancer|August 24, 2012
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final resultsArlene O Siefker-Radtke, Colin P Dinney, Yu Shen, et al.The Journal of Urology|December 11, 2003
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experienceArlene O Siefker-Radtke, Garrett L Walsh, Louis L Pisters, et al.European Urology|May 9, 2012
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer CenterSiobhan P Lynch, Yu Shen, Ashish Kamat, et al.Cancer|December 16, 2006
Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen levelDan Leibovici, Philippe E Spiess, Piyush K Agarwal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancerArlene O Siefker-Radtke, Ashish M Kamat, H Barton Grossman, et al.Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.Clinical Genitourinary Cancer|December 4, 2014
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinomaMatthew T Campbell, Randall E Millikan, Emre Altinmakas, et al.BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.Pageof 4